Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program

CAR-T Digest - August 2020

06 May 2026: Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program

Waiv, formerly known as Owkin Dx, has entered a new collaboration with Daiichi Sankyo to support biomarker discovery for an ADC program, reflecting the growing integration of AI into precision oncology development
The partnership will apply Waiv’s computational pathology platform to early clinical data to identify biomarkers that may help predict patient response to ADC therapy before larger trials begin
Using AI-driven analysis of H&E and IHC tumor samples, the collaboration will explore tumor microenvironment features and multimodal pathology data to uncover potential treatment-response signals
The agreement also highlights a broader industry shift, as ADC developers increasingly focus on biomarker-driven patient stratification and response prediction to improve clinical differentiation and trial success
For Daiichi Sankyo, the collaboration adds an AI-powered precision medicine component to its ADC development strategy, while further strengthening Waiv’s role as a digital pathology and biomarker discovery partner in oncology